{
  "docId": "019de074-cfba-73af-96cf-2b33e6c699c9",
  "docSlug": "90ad9e76f71a7983fe14e2a7d36252ee",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 28,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "appendix_data",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a bulleted list to present clinical safety findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-cfba-73af-96cf-2b33e6c699c9/15",
  "deckHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9",
  "deckJsonHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9.json",
  "deckAnchorHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.85,
        "x": 0.076,
        "y": 0.245
      },
      "kind": "list",
      "text": "AB-729 is generally safe and well-tolerated after repeat dosing for up to 48 weeks\nNo treatment-related SAEs or discontinuations due to AEs\nNo treatment-related Grade 3 or 4 AEs\nNo treatment-related Grade 3 or 4 laboratory abnormalities\nGrade 1 and Grade 2 ALT elevations have improved or stabilized with continued treatment\nInjection site AEs were all Grade 1 (erythema, pain, bruising)\nNo clinically meaningful changes in ECGs or vital signs\nAfter NA treatment discontinuation, no ALT flares have been observed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9132f1fd-3d74-459c-bba1-ad75c8b908d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.243,
        "x": 0.144,
        "y": 0.948
      },
      "kind": "source-note",
      "text": "SAE: Serious Adverse Event | AE: Adverse Event",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5b7a58e-4821-4711-bd33-be3b1bf4c6fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.083,
        "w": 0.498,
        "x": 0.076,
        "y": 0.065
      },
      "kind": "title",
      "text": "AB-729-001 Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a96e63dd-555d-460a-aea7-176e5c9fc51c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "dfdd2820-dcb0-42ce-9eeb-9c499d62e2b1",
      "evidence": "List/bullet points with safety data",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 3,
      "beatId": "708d5cbd-cd14-4361-ab43-54fc6ba4b110",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Our Strategy, Broad Pipeline, AB-729 RNAi Therapeutic, and other solution-focused slides",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 16,
      "from": 10,
      "beatId": "506215b6-f901-48ef-83fa-7b3694884e17",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "AB-729-001 Phase 1a/1b Clinical Trial, Robust HBsAg declines, and AB-729-001 Clinical Trial Key Takeaways",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "94df7ae2-9303-427c-ba30-b5689743bab5",
      "evidence": "The document highlights the significant unmet medical need and the limitations of current treatment options.",
      "position": 1,
      "objective": "What are the consequences of not addressing HBV treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}